AZ-LIMELIGHT-NETWORKS
11.3.2020 12:02:08 CET | Business Wire | Press release
Across the globe people are binge-gaming longer than ever, increasing seven percent from 2019 to an average of four hours and 36 minutes. That’s according to the latest “State of Online Gaming” research report on worldwide consumers’ gaming behaviors and expectations from Limelight Networks Inc., (Nasdaq: LLNW), a leading provider of edge cloud services.
The rise of binge-gaming is an even bigger trend among young gamers. This report showed global respondents ages 18 to 25 binge-play for an average of six hours and 34 minutes, 11 percent longer than one year ago. Japan has the longest average binge-gaming time at more than five and a half hours, and nearly one in ten (9 percent) say they’ve played for more than 15 hours at a time.
While the report shows gamers worldwide spend less time playing video games each week than last year -- averaging six hours and 20 minutes-- their longer binge-gaming sessions can be attributed in part to the rise of anywhere, anytime gaming. Mobile phones are the primary gaming device for worldwide gamers with the preference for smartphone gaming increasing 13 percent from 2019. In addition, this year’s report identified strong interest in console-less gaming services with 44 percent of respondents saying they’re interested in subscribing. Demand for console-less gaming is highest in India where 83 percent of gamers express interest in these services.
Additional insights from the report include:
- Price and performance could limit adoption of console-less gaming. Interest in new console-less gaming platforms is especially high among those who define themselves as experts (71 percent), and among aspiring professional gamers (77 percent). However, concerns with high price points (57 percent) and performance issues such as latency (20 percent) are cited as the top reasons they wouldn’t subscribe. Price sensitivities are highest in the United States (67 percent) and performance concerns are highest in India (28 percent).
- Watching others play video games increased in popularity for younger gamers, sparking the desire to go pro. Gamers ages 18 to 25 watch others play video games online (via platforms such as Twitch or YouTube Gaming) for more than four hours each week and are the most likely to want to turn this hobby into a profession (53 percent).
- Gamers prioritize playing over many daily activities. More than half of gamers (55 percent) have missed sleep to keep playing. Singaporeans are the most likely to choose playing video games over sleeping (60 percent). Many consumers have also skipped meals (32 percent) and showers (22 percent). Younger gamers are the most likely to miss a meal (39 percent) or shower (35 percent) to continue playing.
- Download speed is a top frustration especially for hardcore gamers. The vast majority of global gamers (87 percent) find the process of downloading games frustrating. One-third (32 percent) note slow download speed is their primary concern. Frustrations with download speed are the highest with expert gamers (41 percent) and aspiring professionals (58 percent).
“Players are excited about the flexibility of console-less gaming,” said Michael Milligan, Senior Director at Limelight Networks. “As the world of gaming is being redefined, wide adoption depends on low latency solutions that eliminate frustrating performance disruptions and delays. Keeping gamers engaged requires innovative technology that powers real-time, interactive gaming at the edge.”
The State of Online Gaming report is based on responses from 4,500 consumers in France, Germany, India, Italy, Japan, Singapore, South Korea, the United Kingdom, and the United States age 18 and older who play video games at least once a week. The full report is available here .
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com
, follow us on Twitter
, Facebook
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
